Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biopharmaapac.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Akeso received clinical trial clearance from China's NMPA for its next-generation antibody-drug conjugate AK157D1 targeting B7-H3 in advanced solid tumours, with plans for combination therapies involving proprietary bispecific antibodies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your oncology biotech now faces increased pressure to innovate ADC safety and efficacy; this clearance opens a clear path to advanced clinical testing in China, making combination regimens with bispecific antibodies a must-watch opportunity.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechadcclinical-trialoncologychinabispecific-antibodies